• Explore /
  • Poster
  • / Health-related quality of life (HRQoL) of risk-based patient subgroups with advanced renal cell cancer (aRCC) treated with nivolumab plus cabozantinib (NIVO+CABO) vs sunitinib (SUN) in the CheckMate 9ER trial.

Health-related quality of life (HRQoL) of risk-based patient subgroups with advanced renal cell cancer (aRCC) treated with nivolumab plus cabozantinib (NIVO+CABO) vs sunitinib (SUN) in the CheckMate 9ER trial.

Abstract Poster

Authors

David Cella

David Cella

Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL

David Cella , Toni K. Choueiri , Steven I. Blum , Flavia Ejzykowicz , Joel Wallace , Joshua Zhang , Burcin Simsek , Cristina Ivanescu , Robert J. Motzer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT03141177

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 4527)

DOI

10.1200/JCO.2023.41.16_suppl.4527

Abstract #

4527

Poster Bd #

19

Abstract Disclosures

Similar Posters

First Author: David Cella

First Author: Jens Bedke

First Author: Philippe Barthelemy

First Author: Thomas Powles